Pleno Inc. has secured $15 million in a pre-series A financing led by Medical Excellence Capital and Alexandria Venture Investments. The proceeds will support development of startup Pleno’s Hypercoding multiomic instrument platform. In conjunction with the financing, Pleno named Gregory Lucier as chairman of its board of directors.
Paragon Biosciences-backed Castle Creek Biosciences Inc. pulled off an oversubscribed and upsized preferred stock financing of $112.8 million. The money should let the firm tie the bow on a phase III study and roll out top-line results of its lead ex vivo product candidate for recessive dystrophic epidermolysis bullosa (RDEB) called D-Fi (dabocemagene autoficel, also known as FCX-007).
Elasmogen Ltd. has secured a “transformational” £8 million (US$10 million) in new funding with which to move its shark-based, antibody-like constructs toward the clinic.
Proving that reproduction remains a fecund market for investment, Israeli startup Fairtility Ltd. closed a $15 million series A funding round. Led by Boston-based Gurnet Point Capital with support from Nacre Capital and others, the round boosted Fairtility’s funding to date up to $18.5 million.